{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:02:00Z","timestamp":1784869320617,"version":"3.55.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by FGF23-secreting tumors, resulting in renal phosphate wasting and hypophosphatemic osteomalacia. Low bone mineral density (BMD) in TIO frequently leads to misdiagnosis as the more prevalent primary osteoporosis (POP) and subsequent diagnostic delay. This study characterizes the distinct biochemical profile of TIO and proposes a stepwise diagnostic approach to differentiate it from POP for timely clinical identification and appropriate management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective comparative analysis of 11 TIO patients and 12 POP patients managed at our institution over a 14-year period. Detailed clinical data were collected and compared between groups, including history, physical examination findings, laboratory results, imaging studies, and pathological outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Comparative analysis revealed that, compared with POP patients, TIO patients had significantly lower serum calcium (2.19\u00a0\u00b1\u00a00.1 vs.2.3\u00a0\u00b1\u00a00.1 mmol\/L,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.05), serum phosphorus [0.46 (0.42, 0.6) vs. 1.15 (1.13, 1.23),\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001], and the tubular maximum reabsorption of phosphate per glomerular filtration rate (TmP\/GFR) (0.41\u00a0\u00b1\u00a00.2 vs.1.05\u00a0\u00b1\u00a00.15 mmol\/L,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001). In contrast, ALP was significantly higher in the TIO cohort [317 (177.5, 344) vs. 79.5 (67.75, 86.75) U\/L,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001]. No significant intergroup differences were observed in PTH levels or BMD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We recommend serum phosphate, alkaline phosphatase, and TmP\/GFR tests for symptomatic patients (e.g., bone pain, muscle weakness). Confirmed hypophosphatemia warrants FGF23 testing after excluding other causes of elevation. Subsequent bone X-ray and BMD guides the need for molecular imaging. The diagnostic gold standard comprises: (1) histopathological confirmation of the causative tumor, (2) rapid postoperative serum phosphate normalization, and (3) significant clinical improvement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1899331","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:23:16Z","timestamp":1784866996000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Unveiling the biochemical signature of tumor-induced osteomalacia: implications for distinguishing it from primary osteoporosis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yun","family":"Chai","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, The Affiliated Hospital of Nankai University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwang","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of General Surgery,Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiusong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of PET-CT Diagnostic,Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"He","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2019.07.002","article-title":"Phosphaturic mesenchymal tumors: a review and update","volume":"36","author":"Folpe","year":"2019","journal-title":"Semin Diagn Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.2.497","article-title":"The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting","volume":"86","author":"White","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnac026","article-title":"Tumor-induced osteomalacia: a comprehensive review","volume":"44","author":"Minisola","year":"2023","journal-title":"Endocr Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2010.06.028","article-title":"The bone and the kidney","volume":"503","author":"Mazzaferro","year":"2010","journal-title":"Arch Biochem Biophys"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116064","article-title":"Challenges in the management of tumor-induced osteomalacia (TIO)","volume":"152","author":"Brandi","year":"2021","journal-title":"Bone"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06597-3","article-title":"A low serum alkaline phosphatase may signal hypophosphatasia in osteoporosis clinic patients","volume":"34","author":"Ng","year":"2023","journal-title":"Osteoporos Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-019-00529-7","article-title":"When low bone mineral density and fractures is not osteoporosis","volume":"17","author":"Jha","year":"2019","journal-title":"Curr Osteoporos Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(75)92736-1","article-title":"Nomogram for derivation of renal threshold phosphate concentration","volume":"2","author":"Walton","year":"1975","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-017-0307-y","article-title":"Evaluation of a new fully automated assay for plasma intact FGF23","volume":"101","author":"Souberbielle","year":"2017","journal-title":"Calcif Tissue Int"},{"key":"B11","volume-title":"Soft Tissue and Bone Tumours","year":"2020"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.kint.2022.04.042","article-title":"Tumor-induced osteomalacia","volume":"102","author":"Annamalai","year":"2022","journal-title":"Kidney Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4274\/jcrpe.galenos.2022.2021-8-14","article-title":"Tumor-induced osteomalacia in a boy with maxillary ossifying fibroma","volume":"15","author":"Thi","year":"2023","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/os.13901","article-title":"Tumor-induced osteomalacia: a case report and etiological analysis with literature review","volume":"15","author":"Zhang","year":"2023","journal-title":"Orthop Surg"},{"key":"B15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11657-023-01305-y","article-title":"Occipital bone and tumor-induced osteomalacia: a rare tumor site for an uncommon paraneoplastic syndrome","volume":"18","author":"Colangelo","year":"2023","journal-title":"Arch Osteoporos"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06432-9","article-title":"A literature review to understand the burden of disease in people living with tumour-induced osteomalacia","volume":"33","author":"Minisola","year":"2022","journal-title":"Osteoporos Int"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-021-00843-2","article-title":"Epidemiology of tumor-induced osteomalacia in Denmark","volume":"109","author":"Abrahamsen","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac253","article-title":"Tumor-induced osteomalacia: a systematic review and individual patient's data analysis","volume":"107","author":"Rendina","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01371-w","article-title":"The genetic polymorphisms of XPR1 and SCL34A3 are associated with Fanconi syndrome in Chinese patients of tumor-induced osteomalacia","volume":"44","author":"Jiang","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-020-05369-1","article-title":"Long-term bone mineral density changes after surgical cure of patients with tumor-induced osteomalacia","volume":"31","author":"Colangelo","year":"2020","journal-title":"Osteoporos Int"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-022-01005-8","article-title":"Tumor-induced osteomalacia: a systematic clinical review of 895 cases","volume":"111","author":"Bosman","year":"2022","journal-title":"Calcif Tissue Int"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.ej16-0587","article-title":"The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases","volume":"64","author":"Feng","year":"2017","journal-title":"Endocr J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2008.10.052","article-title":"The Klotho gene family as a regulator of endocrine fibroblast growth factors","volume":"299","author":"Kurosu","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00189","article-title":"FGF23 actions on target tissues-with and without Klotho","volume":"9","author":"Richter","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"17044","DOI":"10.1038\/nrdp.2017.44","article-title":"Tumour-induced osteomalacia","volume":"3","author":"Minisola","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2606","article-title":"FGF23 regulates bone mineralization in a 1,25(OH)2 D3 and Klotho-independent manner","volume":"31","author":"Murali","year":"2016","journal-title":"J Bone Miner Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10558","article-title":"FGF23 and vitamin D metabolism","volume":"5","author":"Latic","year":"2021","journal-title":"JBMR Plus"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/en.143.8.3179","article-title":"Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo","volume":"143","author":"Shimada","year":"2002","journal-title":"Endocrinology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-021-00709-4","article-title":"FGF23 and hypophosphatemic rickets\/osteomalacia","volume":"19","author":"Takashi","year":"2021","journal-title":"Curr Osteoporos Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1546","article-title":"Mechanism of FGF23 processing in fibrous dysplasia","volume":"27","author":"Bhattacharyya","year":"2012","journal-title":"J Bone Miner Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001788","article-title":"Post-transplant hypophosphatemia: tertiary 'hyper-phosphatoninism'?","volume":"70","author":"Bhan","year":"2006","journal-title":"Kidney Int"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2013.02.014","article-title":"Reversible increase in FGF23 in a hypophosphatemic renal and bone disease linked to antiviral therapy by adefovir","volume":"80","author":"Ichchou","year":"2013","journal-title":"Joint Bone Spine"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2008.02.014","article-title":"Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement","volume":"42","author":"Endo","year":"2008","journal-title":"Bone"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30080541","article-title":"Phosphaturic mesenchymal tumors with or without phosphate metabolism derangements","volume":"30","author":"Montanari","year":"2023","journal-title":"Curr Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870415)59:8<1442::aid-cncr2820590810>3.0.co;2-q","article-title":"Phosphaturic mesenchymal tumors: a polymorphous group causing osteomalacia or rickets","volume":"59","author":"Weidner","year":"1987","journal-title":"Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200401000-00001","article-title":"Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature","volume":"28","author":"Folpe","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinimag.2019.04.007","article-title":"Tumor-induced osteomalacia - current imaging modalities and a systematic approach for tumor localization","volume":"56","author":"Rayamajhi","year":"2019","journal-title":"Clin Imaging"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1899331\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:23:18Z","timestamp":1784866998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1899331\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":37,"alternative-id":["10.3389\/fendo.2026.1899331"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1899331","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"1899331"}}